Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Monoclonal antibody therapy in Langerhans cell histiocytosis--feasible and reasonable?

Literature DB >> 8075008

Monoclonal antibody therapy in Langerhans cell histiocytosis--feasible and reasonable?

Abstract

Many recent studies have demonstrated the range of disorders in which monoclonal antibodies have a clinical role. The monoclonal antibody NA1/34, directed against a surface antigen present on lesional cells ('LCH cells'), has been found to localise in vivo to sites of disease. This review explores the possible applications and limitations of monoclonal antibody based-therapy in Langerhans cell histiocytosis.

Mesh：

Substances：

Year: 1994 PMID： 8075008 PMCID： PMC2149709

Source DB: PubMed Journal: Br J Cancer Suppl ISSN： 0306-9443

12 in total

1. Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors: G Köhler; C Milstein
Journal: Nature Date: 1975-08-07 Impact factor: 49.962

Review 2. Monoclonal antibody-based therapies of leukemia and lymphoma.

Authors: M L Grossbard; O W Press; F R Appelbaum; I D Bernstein; L M Nadler
Journal: Blood Date: 1992-08-15 Impact factor: 22.113

Review 3. Current controversies. Histiocytosis-X.

Authors: J McLelland; J Pritchard; A C Chu
Journal: Hematol Oncol Clin North Am Date: 1987-03 Impact factor: 3.722

4. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.

Authors: C M Lockwood; S Thiru; J D Isaacs; G Hale; H Waldmann
Journal: Lancet Date: 1993-06-26 Impact factor: 79.321

5. A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody.

Authors: A J McMichael; J R Pilch; G Galfré; D Y Mason; J W Fabre; C Milstein
Journal: Eur J Immunol Date: 1979-03 Impact factor: 5.532

6. Humanised monoclonal antibody therapy for rheumatoid arthritis.

Authors: J D Isaacs; R A Watts; B L Hazleman; G Hale; M T Keogan; S P Cobbold; H Waldmann
Journal: Lancet Date: 1992-09-26 Impact factor: 79.321

7. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.

Authors: O W Press; J F Eary; F R Appelbaum; P J Martin; C C Badger; W B Nelp; S Glenn; G Butchko; D Fisher; B Porter
Journal: N Engl J Med Date: 1993-10-21 Impact factor: 91.245

8. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

Authors: E Oosterwijk; N H Bander; C R Divgi; S Welt; J C Wakka; R D Finn; E A Carswell; S M Larson; S O Warnaar; G J Fleuren
Journal: J Clin Oncol Date: 1993-04 Impact factor: 44.544

9. Reshaping human antibodies for therapy.

Authors: L Riechmann; M Clark; H Waldmann; G Winter
Journal: Nature Date: 1988-03-24 Impact factor: 49.962

10. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies.

Authors: J R Ortaldo; C Woodhouse; A C Morgan; R B Herberman; D A Cheresh; R Reisfeld
Journal: J Immunol Date: 1987-05-15 Impact factor: 5.422

5 in total

Review 1. Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement.

Authors: E Michel Azouz; Gaurav Saigal; Maria M Rodriguez; Antonello Podda
Journal: Pediatr Radiol Date: 2004-07-28

2. Intralesional corticosteroid therapy for mandibular Langerhans cell histiocytosis preserving the intralesional tooth germ.

Authors: Antonios Moralis; Martin Kunkel; Norbert Kleinsasser; Urs Müller-Richter; Torsten Eugen Reichert; Oliver Driemel
Journal: Oral Maxillofac Surg Date: 2008-07